These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 31049836)
1. A Systematic Review of the Health Economics of Pompe Disease. Schoser B; Hahn A; James E; Gupta D; Gitlin M; Prasad S Pharmacoecon Open; 2019 Dec; 3(4):479-493. PubMed ID: 31049836 [TBL] [Abstract][Full Text] [Related]
2. The humanistic burden of Pompe disease: are there still unmet needs? A systematic review. Schoser B; Bilder DA; Dimmock D; Gupta D; James ES; Prasad S BMC Neurol; 2017 Nov; 17(1):202. PubMed ID: 29166883 [TBL] [Abstract][Full Text] [Related]
3. A systematic review of economic evaluations of enzyme replacement therapy in Lysosomal storage diseases. Katsigianni EI; Petrou P Cost Eff Resour Alloc; 2022 Sep; 20(1):51. PubMed ID: 36123734 [TBL] [Abstract][Full Text] [Related]
4. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Shepherd J; Jones J; Takeda A; Davidson P; Price A Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease. Kanters TA; van der Ploeg AT; Kruijshaar ME; Rizopoulos D; Redekop WK; Rutten-van Mӧlken MPMH; Hakkaart-van Roijen L Orphanet J Rare Dis; 2017 Dec; 12(1):179. PubMed ID: 29237491 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of enzyme replacement therapy (ERT) for treatment of infantile-onset Pompe disease (IOPD) in the Iranian pharmaceutical market. Hashempour R; Davari M; Pourreza A; Alaei M; Ahmadi B Intractable Rare Dis Res; 2020 Aug; 9(3):130-136. PubMed ID: 32844068 [TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of enzyme replacement therapy (ERT) for the infantile form of Pompe disease: comparing a high-income country's approach (England) to that of a middle-income one (Colombia). Castro-Jaramillo HE Rev Salud Publica (Bogota); 2012; 14(1):143-55. PubMed ID: 23250322 [TBL] [Abstract][Full Text] [Related]
8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
9. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208 [TBL] [Abstract][Full Text] [Related]
10. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer. Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100 [TBL] [Abstract][Full Text] [Related]
11. Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies. Xie F; Kovic B; Jin X; He X; Wang M; Silvestre C Pharmacoeconomics; 2016 Nov; 34(11):1087-1100. PubMed ID: 27339668 [TBL] [Abstract][Full Text] [Related]
12. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder. Bereza BG; Machado M; Einarson TR Clin Ther; 2009 Jun; 31(6):1279-308. PubMed ID: 19695395 [TBL] [Abstract][Full Text] [Related]
13. Pompe disease in Austria: clinical, genetic and epidemiological aspects. Löscher WN; Huemer M; Stulnig TM; Simschitz P; Iglseder S; Eggers C; Moser H; Möslinger D; Freilinger M; Lagler F; Grinzinger S; Reichhardt M; Bittner RE; Schmidt WM; Lex U; Brunner-Krainz M; Quasthoff S; Wanschitz JV J Neurol; 2018 Jan; 265(1):159-164. PubMed ID: 29181627 [TBL] [Abstract][Full Text] [Related]
14. Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes-the Pompe disease burden scale. Hundsberger T; Schoser B; Leupold D; Rösler KM; Putora PM J Neurol; 2019 Aug; 266(8):2010-2017. PubMed ID: 31104135 [TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation. Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331 [TBL] [Abstract][Full Text] [Related]
16. Health and economic outcomes of newborn screening for infantile-onset Pompe disease. Richardson JS; Kemper AR; Grosse SD; Lam WKK; Rose AM; Ahmad A; Gebremariam A; Prosser LA Genet Med; 2021 Apr; 23(4):758-766. PubMed ID: 33281187 [TBL] [Abstract][Full Text] [Related]
17. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Dangouloff T; Botty C; Beaudart C; Servais L; Hiligsmann M Orphanet J Rare Dis; 2021 Jan; 16(1):47. PubMed ID: 33485382 [TBL] [Abstract][Full Text] [Related]
18. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574 [TBL] [Abstract][Full Text] [Related]